Unknown

Dataset Information

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review.


ABSTRACT:

Background

Drug-resistant tuberculosis (DR-TB) is considered to be a public health threat and is difficult to cure, requiring a lengthy treatment with potent, potentially toxic drugs. The novel antimicrobial agent bedaquiline has shown promising results for patients with DR-TB, improving the rate of culture conversion and reducing TB-related mortality. However, increasing numbers of cases with acquired bedaquiline resistance (ABR) have been reported in recent years.

Methods

This systematic review aimed to assess the frequency of ABR and characteristics of patients acquiring it. Studies showing data on sequential bedaquiline drug-susceptibility testing in patients treated with a bedaquiline-containing regimen were included. The databases CENTRAL, PubMed and Embase were manual

SUBMITTER: Mallick JS 

PROVIDER: S-EPMC8963286 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature